Krystal Biotech Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional ...
PITTSBURGH, Sept. 22, 2017 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (“Krystal”) (NASDAQ:KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from dermatological diseases, today announced the …